Maha Hussain, MD, FACP, FASCO, reflects on the path that led her into genitourinary cancers, and the challenges she has overcome in her career while offering advice to young oncologists just getting started in the field.
Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Feinberg School of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr Hussain has been a leading oncologist in the genitourinary cancer field, and is focused on the development of novel therapeutics integrating scientific advances into clinical trials in prostate and bladder cancer.
Thus far, she has had an impressive career in oncology, including her contribution to research that led to the FDA approval of docetaxel for the treatment of men with advanced prostate cancer. As a lead investigator in an international collaborative trial, she also evaluated optimal schedules of androgen deprivation therapy for patients with newly diagnosted metastatic prostate cancer.
OncLive recognized Dr Hussain as a Giant of Cancer Care® in Genitourinary Cancers in 2015.
In our exclusive interview, Dr. Hussain reflected on the path that led her into GU cancers, pivotal research she has been a part of and strategies in the pipeline she is intrigued by, and the challenges she has overcome in her career while offering advice to young oncologists just getting started in the field.